Skip to main content
. 2012 Feb 23;5(1):65–70. doi: 10.1111/j.1752-8062.2011.00375.x

Figure 1.

Figure 1

FCH PET/CT of a patient with metastatic hormone‐refractory prostate cancer. Prior to chemotherapy, the FCH PET/CT image ( A ) demonstrates seven metabolically active skeletal metastases involving multiple thoracic and lumbar vertebrae (arrows). Posttreatment FCH PET/CT performed following three cycles of chemotherapy ( B ) demonstrates persistently increased activity in only four of the seven metastases identified on the pretreatment scan (arrows).